Photobiomodulation Therapy

FDA Approved Valeda™ Photobiomodulation (PBM) Therapy

Valeda™ PBM is the first FDA-authorized treatment for eligible patients with early and intermediate dry age-related macular degeneration. Clinical studies demonstrated that 84% of treated patients maintained or improved vision at approximately two years, and more than 60% experienced at least a one-line improvement in visual acuity. Treatment consists of three treatments per week for three consecutive weeks, repeated every four months.

Supports retinal health to improve and maintain vision for Early Dry AMD, Intermediate Dry AMD, Medium/Large Drusen and Non-central GA BCVA. Enjoy a comfortable office treatment with no injections, no dilation, no anesthesia and no speculum.

Ask us about incorporating Valeda™ PBM Therapy into your dry AMD care plan.